James M Feeney1, Elizabeth Santone, Monica DiFiori, Lilla Kis, Vijay Jayaraman, Stephanie C Montgomery. 1. From the Department of Surgery (J.M.F., V.J., S.C.M.), Saint Francis Hospital and Medical Center, Hartford, Connecticut; University of Connecticut School of Medicine (J.M.F., E.S., V.J., S.C.M.), Farmington, Connecticut; and Trinity College (M.D., L.K.), Hartford, Connecticut.
Abstract
BACKGROUND: Falls represent the leading cause of traumatic brain injury in adults older than 65, with nearly one third experiencing a fall each year. Evidence suggests that up to 0.5% of anticoagulated patients suffer from intracranial hemorrhage (ICH) annually. Direct oral anticoagulants (DOACs) have become an increasingly popular alternative to warfarin for anticoagulation; however, there is a dearth of research regarding the safety of DOACs, in particular on the outcome of traumatic ICH while taking DOACs. METHODS: We queried our Trauma Quality Improvement Project registry for patients who presented with traumatic intracranial hemorrhage during anticoagulant use. Patients were grouped into those prescribed warfarin and patients prescribed DOAC medications. The groups were compared with respect to age, gender, Glasgow Coma Score (GCS) on arrival, Abbreviated Injury Scale (AIS) (head), Injury Severity Score (ISS), mortality, need for operative intervention, hospital and ICU lengths of stay, proportion of patients transfused (and their transfusion requirements), and rates of discharge to skilled nursing facility. Poisson regression was conducted to determine the relationship between mortality and treatment group while controlling for covariates (comorbidities, ISS). RESULTS: There were no differences between DOAC and warfarin groups in terms of age, gender, median ISS, median AIS head, or median admission GCS. Mechanisms of injury, median hospital and ICU lengths of stay, ICU free days, and transfusion requirements were also not significantly different.DOAC use was associated with significantly lower mortality (4.9% vs. 20.8%; p < 0.008) and a lower rate of operative intervention (8.2% vs. 26.7%; p = 0.023) when compared with warfarin. Excluding patients who died, the observed rate of discharge to skilled nursing facility was lower in the DOAC group (28.8% compared with 39.7%; p = 0.03). Multivariate Poisson regression analysis demonstrated that warfarin use was associated with an increased mortality when controlling for injury severity, and comorbidities. CONCLUSIONS: We report improved mortality and reduced rates of operative intervention in patients with traumatic ICH associated with DOACs compared with a similar group taking warfarin. We also noted an association with decreased rate of discharge to SNF in patients taking DOACs compared with warfarin. LEVEL OF EVIDENCE: Therapeutic study, level IV.
BACKGROUND: Falls represent the leading cause of traumatic brain injury in adults older than 65, with nearly one third experiencing a fall each year. Evidence suggests that up to 0.5% of anticoagulated patients suffer from intracranial hemorrhage (ICH) annually. Direct oral anticoagulants (DOACs) have become an increasingly popular alternative to warfarin for anticoagulation; however, there is a dearth of research regarding the safety of DOACs, in particular on the outcome of traumatic ICH while taking DOACs. METHODS: We queried our Trauma Quality Improvement Project registry for patients who presented with traumatic intracranial hemorrhage during anticoagulant use. Patients were grouped into those prescribed warfarin and patients prescribed DOAC medications. The groups were compared with respect to age, gender, Glasgow Coma Score (GCS) on arrival, Abbreviated Injury Scale (AIS) (head), Injury Severity Score (ISS), mortality, need for operative intervention, hospital and ICU lengths of stay, proportion of patients transfused (and their transfusion requirements), and rates of discharge to skilled nursing facility. Poisson regression was conducted to determine the relationship between mortality and treatment group while controlling for covariates (comorbidities, ISS). RESULTS: There were no differences between DOAC and warfarin groups in terms of age, gender, median ISS, median AIS head, or median admission GCS. Mechanisms of injury, median hospital and ICU lengths of stay, ICU free days, and transfusion requirements were also not significantly different.DOAC use was associated with significantly lower mortality (4.9% vs. 20.8%; p < 0.008) and a lower rate of operative intervention (8.2% vs. 26.7%; p = 0.023) when compared with warfarin. Excluding patients who died, the observed rate of discharge to skilled nursing facility was lower in the DOAC group (28.8% compared with 39.7%; p = 0.03). Multivariate Poisson regression analysis demonstrated that warfarin use was associated with an increased mortality when controlling for injury severity, and comorbidities. CONCLUSIONS: We report improved mortality and reduced rates of operative intervention in patients with traumatic ICH associated with DOACs compared with a similar group taking warfarin. We also noted an association with decreased rate of discharge to SNF in patients taking DOACs compared with warfarin. LEVEL OF EVIDENCE: Therapeutic study, level IV.
Authors: Chad Hall; Shannon Essler; Jad Dandashi; Matthew Corrigan; Yolanda Muñoz-Maldonado; Andrew Juergens; Scott Wieters; Dorian Drigalla; Justin L Regner Journal: Proc (Bayl Univ Med Cent) Date: 2019-03-21
Authors: Walter Bialkowski; Sylvia Tan; Alan E Mast; Joseph E Kiss; Daryl Kor; Jerome Gottschall; Yanyun Wu; Nareg Roubinian; Darrell Triulzi; Steve Kleinman; Young Choi; Donald Brambilla; Ann Zimrin Journal: Thromb Res Date: 2019-11-25 Impact factor: 3.944
Authors: Christopher Beynon; Steffen Brenner; Alexander Younsi; Timolaos Rizos; Jan-Oliver Neumann; Johannes Pfaff; Andreas W Unterberg Journal: Neurocrit Care Date: 2019-04 Impact factor: 3.210
Authors: Thaddeus J Puzio; Patrick B Murphy; Heather R Kregel; Ryan C Ellis; Travis Holder; Michael W Wandling; Charles E Wade; Lillian S Kao; Michelle K McNutt; John A Harvin Journal: J Am Coll Surg Date: 2021-03-22 Impact factor: 6.113
Authors: Juan Antonio Llompart-Pou; Jon Pérez-Bárcena; Mario Chico-Fernández; Marcelino Sánchez-Casado; Joan Maria Raurich Journal: World J Crit Care Med Date: 2017-05-04